ProPhase Labs, Inc. (PRPH) P/E Ratio History
Historical price-to-earnings valuation from 1997 to 2023
Loading P/E history...
PRPH Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, ProPhase Labs, Inc. (PRPH) trades at a price-to-earnings ratio of -0.0x, with a stock price of $0.12 and trailing twelve-month earnings per share of $-1.00.
The current P/E is 100% below its 5-year average of 147.2x. Over the past five years, PRPH's P/E has ranged from a low of 1.8x to a high of 1037.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, PRPH trades at a 100% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, PRPH trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PRPH DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PRPH P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $176B | 26.8 | 12.67 | +7%Best | |
| $124B | 34.9 | - | -5% | |
| $34B | 26.0Lowest | 1.76Best | +3% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
PRPH Historical P/E Data (1997–2023)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $3.81 | $0.32 | 11.8x | -91% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $4.82 | $0.96 | 5.0x | -96% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $5.64 | $1.80 | 3.1x | -98% |
| FY2022 Q2 | $6.34 | $1.49 | 4.3x | -97% | |
| FY2022 Q1 | $3.50 | $1.01 | 3.5x | -97% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $3.59 | $0.40 | 9.0x | -93% |
| FY2017 Q4 | Sun Dec 31 2017 00:00:00 GM | $4.34 | $2.30 | 1.9x | -99% |
| FY2017 Q3 | Sat Sep 30 2017 00:00:00 GM | $4.28 | $2.25 | 1.9x | -99% |
| FY2017 Q2 | Fri Jun 30 2017 00:00:00 GM | $4.18 | $2.31 | 1.8x | -99% |
| FY2017 Q1 | Fri Mar 31 2017 00:00:00 GM | $4.54 | $2.38 | 1.9x | -99% |
| FY2013 Q4 | $3.22 | $0.03 | 122.4x | -10% | |
| FY2013 Q3 | Mon Sep 30 2013 00:00:00 GM | $3.80 | $0.02 | 190.0x | +39% |
Average P/E for displayed period: 136.3x
See PRPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PRPH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PRPH vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPRPH — Frequently Asked Questions
Quick answers to the most common questions about buying PRPH stock.
Is PRPH stock overvalued or undervalued?
PRPH current P/E: -0.0x. 5-year average P/E: 147.2x. Percentile: N/A.
How does PRPH's valuation compare to peers?
ProPhase Labs, Inc. P/E of -0.0x compares to sector median of 22.3x. Sector comparison provides relative valuation context.
What is PRPH's PEG ratio?
PRPH PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1997-2023.